RxDoctor Payments Data

Courtney Reints

Pediatric Endocrinology · Des Moines, IANPI 1700417169

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $111,146 of the $174,463 with a category attached, or 63.7%. 26 manufacturers reported payments, led by Novo Nordisk at 59.0% of the total.

$174,463in general payments, 2019–2025

Across 524 payments — averaging $332.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$103K
  • Kyowa Kirin, Inc.$37K
  • Ascendis Pharma Endocrinology Inc$9K
  • AbbVie$7K
  • Neurocrine Biosciences, Inc.$6K
  • Biomarin Pharmaceutical Inc.$5K
  • plus $8K from 20 others

What the payments were for

  • Consulting fees$12,5987%
  • Speaking & faculty fees$111,14664%
  • Travel & lodging$40,12023%
  • Food & beverage$10,4366%
  • Education$1620%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric endocrinology providers in Iowato place this figure against a meaningful peer group, so we don't.

Other pediatric endocrinology in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →